Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has been dosed in a Phase I clinical study (ABSK043-101) for its in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor, ABSK043, in patients with advanced solid tumors in China. The drug has previously completed multiple dose evaluations outside of China and dosed the first patient in an overseas Phase I clinical study, which received clinical approval in Australia in August 2021.
ABSK043: Drug Overview
ABSK043 is a small molecule PD-L1 inhibitor characterized by high bioavailability and selectivity. It is designed to address the limitations of current PD-1/PD-L1 antibodies, including high costs, poor blood-brain barrier permeability, and immunogenicity. Preclinical data demonstrate that ABSK043 effectively inhibits the PD-1/PD-L1 interaction, relieves PD-L1-mediated inhibition of T cell activation, and exhibits strong antitumor efficacy across multiple preclinical models.
Company Overview and Pipeline
Abbisko Therapeutics is focused on small molecule cancer precision medicine and small molecule tumor immunotherapy. The company has a robust product pipeline comprising 15 drug candidates, with 13 clinical trial approvals across four countries and regions globally. The initiation of the Phase I clinical study for ABSK043 marks another significant milestone in Abbisko’s commitment to advancing innovative cancer therapies.-Fineline Info & Tech
